|
Jun 26
|
Vor, with new CEO, changes course to target autoimmune disease
|
|
Jun 26
|
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
|
|
Jun 16
|
PureTech Health: Results of Annual General Meeting
|
|
May 22
|
PureTech to Present at the Jefferies Global Healthcare Conference
|
|
May 20
|
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
|
|
Mar 11
|
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
|
|
Feb 12
|
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
|
|
Jan 27
|
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
|